Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sexually transmitted diseases: an update

M A Kraynak1, L C Knodel

  • 1Department of Pharmacology, University of Texas Health Science Center at San Antonio, USA.

American Pharmacy
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drug utilization review of sedative/hypnotic agents in Texas Medicaid patients. Texas Medicaid Vendor Drug Program Drug Utilization Review Board.

Journal of the American Pharmaceutical Association (Washington, D.C. : 1996)·2000
Same author

Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·1998
Same author

Pharmaceutical aspects of docetaxel.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same author

A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements.

Pharmacotherapy·1997
Same journal

Dispensing errors and counseling in community practice.

American pharmacy·1995
Same journal

The role of the pharmacist in improving asthma care. National Asthma Education and Prevention Program.

American pharmacy·1995
Same journal

Attention-deficit hyperactivity disorder: the pharmacist's role.

American pharmacy·1995
See all related articles

Pharmacists play a key role in managing sexually transmitted diseases (STDs) by ensuring correct medication use and patient compliance with updated treatment guidelines. This helps prevent antibiotic resistance and improves health outcomes.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Public Health

Background:

  • The 1993 CDC treatment guidelines for STDs introduced new medications and treatment approaches compared to previous guidelines.
  • Pharmacists face evolving challenges in selecting and managing STD therapies due to new drug formulations, costs, and treatment durations.

Purpose of the Study:

  • To highlight the critical role of pharmacists in implementing updated STD treatment guidelines.
  • To emphasize the importance of pharmacist intervention in ensuring patient compliance and preventing antimicrobial resistance.

Main Methods:

  • Review of the 1993 CDC STD treatment guidelines, focusing on changes from prior recommendations.
  • Analysis of factors pharmacists must consider when selecting STD medications for formularies, including dosage, cost, and duration.

Related Experiment Videos

  • Discussion of strategies for pharmacists to verify disease processes and ensure patient compliance with single-dose or short-course therapies.

    • Main Results:

    • Updated guidelines include recently marketed medications for STD treatment.
    • Pharmacists must evaluate dosage forms (oral vs. intramuscular), cost, and treatment length (e.g., once-daily vs. 7-day courses).
    • Verification of the disease process and direct administration of therapy can enhance patient compliance.

    Conclusions:

    • Pharmacists are essential in optimizing STD treatment by understanding guideline changes and medication properties.
    • Proactive pharmacist involvement in verifying prescriptions and ensuring compliance can mitigate the development of drug resistance.
    • Implementing programs to ensure adherence to STD therapies is crucial for effective disease management and public health.